HomeComparePGUUF vs JNJ

PGUUF vs JNJ: Dividend Comparison 2026

PGUUF yields 6.50% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PGUUF wins by $11788.35M in total portfolio value
10 years
PGUUF
PGUUF
● Live price
6.50%
Share price
$0.61
Annual div
$0.04
5Y div CAGR
95.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11788.38M
Annual income
$11,372,698,707.34
Full PGUUF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — PGUUF vs JNJ

📍 PGUUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPGUUFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PGUUF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PGUUF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PGUUF
Annual income on $10K today (after 15% tax)
$552.38/yr
After 10yr DRIP, annual income (after tax)
$9,666,793,901.24/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, PGUUF beats the other by $9,666,789,915.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PGUUF + JNJ for your $10,000?

PGUUF: 50%JNJ: 50%
100% JNJ50/50100% PGUUF
Portfolio after 10yr
$5894.20M
Annual income
$5,686,351,698.37/yr
Blended yield
96.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PGUUF
No analyst data
Altman Z
1.7
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PGUUF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPGUUFJNJ
Forward yield6.50%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR95.8%28%
Portfolio after 10y$11788.38M$30.3K
Annual income after 10y$11,372,698,707.34$4,689.40
Total dividends collected$11759.37M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PGUUF vs JNJ ($10,000, DRIP)

YearPGUUF PortfolioPGUUF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,972$1,272.42$10,592$272.30+$1.4KPGUUF
2$15,598$2,787.67$11,289$357.73+$4.3KPGUUF
3$23,336$6,646.03$12,123$472.89+$11.2KPGUUF
4$43,164$18,194.71$13,141$629.86+$30.0KPGUUF
5$107,770$61,584.47$14,408$846.81+$93.4KPGUUF
6$396,682$281,367.78$16,021$1,151.60+$380.7KPGUUF
7$2,319,614$1,895,163.91$18,122$1,588.22+$2.30MPGUUF
8$22,761,096$20,279,109.60$20,930$2,228.20+$22.74MPGUUF
9$388,483,413$364,129,040.50$24,792$3,191.91+$388.46MPGUUF
10$11,788,375,960$11,372,698,707.34$30,274$4,689.40+$11788.35MPGUUF

PGUUF vs JNJ: Complete Analysis 2026

PGUUFStock

Prosegur Cash, S.A., together with its subsidiaries, provides cash cycle management solutions and automating payments in retail establishments, ATM management for financial institutions, business, government agencies, central banks, mints, and jewellery stores. The company offers national and international transport services, including collection, transport, custody, and deposit services for funds and other valuables that include jewellery, artworks, precious metals, electronic devices, voting ballots, and legal evidence. It also provides cash processing and automation services, such as counting, processing, and packaging, as well as coin recycling, cash flow control, and monitoring systems; ATM solutions comprising planning, loading, monitoring, first- and second-tier maintenance, and balancing services; and cash planning and forecasting services. In addition, the company offers self-service cash machines that provide cash deposit, recycling, bank notes and coins dispensing, and collection, payment management, invoice payments services; and added-value outsourcing services for banks, such as multiagency, cheque processing, and related administrative services, as well as teller outsourcing service. It serves in Spain, Portugal, Germany, Luxembourg, Argentina, Brazil, Chile, Peru, Uruguay, Paraguay, Colombia, the Philippines, Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Ecuador, Mexico, India, Singapore, Indonesia, and Australia. The company was incorporated in 2016 and is headquartered in Madrid, Spain. Prosegur Cash, S.A. is a subsidiary of Prosegur Compañía de Seguridad, S.A.

Full PGUUF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PGUUF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PGUUF vs SCHDPGUUF vs JEPIPGUUF vs OPGUUF vs KOPGUUF vs MAINPGUUF vs ABBVPGUUF vs MRKPGUUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.